SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
Paris, March 19, 2021 – SparingVision ("the Company"), a genomic medicine company developing vision saving treatments for ocular diseases, announces today that three abstracts highlighting the company’s recent research into ocular diseases and its lead gene therapy treatment SPVN06 have been accepted for the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, to be held virtually from 1-7 May. The three abstracts will be given as poster presentations for which the details can be found below.
Title: SPVN06, a Novel Mutation-Independent AAV-based Gene Therapy, Protects Cone Degeneration in a Pig Model of Retinitis Pigmentosa
Date and Time: May 3, 2021 from 11:15 AM to 1:00 PM EDT
Presenter: Dr. Jennifer Noel, University of Louisville
Session Title: Drug delivery and Gene Therapy
Title: Correlations between progression markers in rod-cone dystrophy due to mutations in RHO, PDE6A, or PDE6B
Date and Time: May 3, 2021 from 4:30 PM to 6:15 PM EDT
Presenter: Dr. Daniel Chung, Chief Medical Officer, SparingVision
Session Title: Visual Impairment - Assessment and Measurement
Title: A 1-Month Toxicology and Biodistribution NHP Pilot Study Evaluating a Single Subretinal Bilateral Administration of SPVN06 - A Novel AAV-Based Gene Therapy for the Treatment of Rod-Cone Dystrophies Agnostic of the Causative Mutation
Date and Time: May 5, 2021 from 2:45 PM to 4:30 PM EDT
Presenter: Dr. Melanie Marie, SparingVision
Session Title: AMD and retinal physiology
**ENDS**
Contacts:
SparingVision | |
Stéphane Boissel | President and CEO |
Nathalie Trepo | Investor Relations nathalie.trepo@sparingvision.com |
Consilium Strategic Communications | |
Amber Fennell, Olivia Manser, Alexander Bridge | +44 (0)20 3709 5700 sparingvision@consilium-comms.com |
NOTES TO EDITORS:
About SparingVision:
SparingVision is a genomic medicines company, translating pioneering science into vision saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is SPVN06, a gene independent treatment for retinitis pigmentosa (RP), the most common inherited retinal disease affecting two million people worldwide. SPVN06 could form the basis of a suite of new sight saving treatments as it could be applicable to many other retinal diseases, regardless of genetic cause.
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.
About SPVN06:
SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of cone photoreceptors, which inevitably leads to blindness in patients with rod-cone dystrophies (RCD). SparingVision’s primary disease target is Retinitis Pigmentosa (RP), one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved to treat RP patients independently of their genetic background. This approach is potentially applicable to many more diseases where the loss of rods is known to be an early signal of the disease. First-in-man trials, with SPVN06 in patients with RP, will be commencing in H2 2021.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
INTESA SANPAOLO S.P.A.15.7.2025 20:03:19 CEST | Press release
Infrastructure: IMI CIB promotes dialogue in London on the UK’s €846 billion plan
Mohawk Industries, Inc.15.7.2025 19:00:00 CEST | Press release
Mohawk Impact Report Highlights Progress
Epiq15.7.2025 17:39:14 CEST | Press release
Epiq Wins Todd & Weld LLP Office Services Outsourcing Business
Siili Solutions Oyj15.7.2025 17:30:00 CEST | Press release
Siili Solutions Plc: Share Repurchase 15.7.2025
Baltic Horizon Fund / Northern Horizon Capital15.7.2025 17:15:00 CEST | Press release
Baltic Horizon Fund publishes its NAV for June 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom